ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Caplin Point Laboratories Ltd

NSE: CAPLIPOINT · BSE: 524742 · Pharmaceuticals & Biotechnology · 27 announcements

Share price
₹2,520.30
Market cap
₹19,157 Cr
Revenue (annual)
₹2,187 Cr
Net profit (annual)
₹641.2 Cr
P/E (TTM)
28.8×Sector 43.8×
Promoter holding
70.57%+0.00% QoQ
FII holding
5.72%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

12:34 IST BSE
Regulatory Approval

Caplin Point Laboratories Regulatory Approval

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final USFDA approval for its Calcium Gluconate Injection USP. The product addresses acute symptomatic hypocalcemia and targets a US market with annual sales of approximately ₹674.5 Crore ($71 million). This approval strengthens the company's injectable portfolio in the regulated US market.

Value
₹674.5 Cr